（编辑 袁冠琳） 证券日报网讯 上海莱士10月24日在互动平台回答投资者提问时表示，公司非常重视全体股东的合理投 资回报，制定分红方案时，既会考量股东合理回报，也兼顾公司发展规划、财务状况等因素。目前，公 司需储备相应的战略资金，以支撑未来"脱浆战略"的稳步落地，助力公司实现关键阶段的战略转型，为 长期发展奠定坚实基础。后续公司将持续优化经营，在平衡公司发展与股东回报的基础上，合理规划分 红政策。 ...

（文章来源：每日经济新闻） 上海莱士（002252.SZ）10月24日在投资者互动平台表示，目前，广西莱士处于试生产阶段，待完成试 生产及药品注册审批后，将逐步提升产量，达到稳定的运营状态。血液制品行业具有特殊属性，产量主 要受采浆能力以及药品监管审批等诸多因素影响，公司将尽快推动广西莱士产品获批上市，实现稳定运 营。 每经AI快讯，有投资者在投资者互动平台提问：公司在回复投资者提及广西莱士已经试产，请问该公 司的产能爬坡期会持续多少年？ ...

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

证券日报网讯上海莱士（002252）10月17日在互动平台回答投资者提问时表示，截至2025年10月10日， 公司股东总户数为110316户。 ...

证券之星消息，10月16日，上海莱士（002252）融资买入4258.23万元，融资偿还3894.06万元，融资净 买入364.17万元，融资余额12.88亿元，近3个交易日已连续净买入累计1429.9万元，近20个交易日中有 13个交易日出现融资净买入。 | 交易日 | 融资净买入(元) | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | | 2025-10-16 | 364.17万 | 12.88亿 | 2.89% | | 2025-10-15 | 811.38万 | 12.84亿 | 2.87% | | 2025-10-14 | 254.35万 | 12.76亿 | 2.85% | | 2025-10-13 | -1203.53万 | 12.74亿 | 2.86% | | 2025-10-10 | 263.91万 | 12.86亿 | 2.85% | 融券方面，当日融券卖出1.4万股，融券偿还3600.0股，融券净卖出1.04万股，融券余量72.36万股，近3 个交易日已连续净卖出累计6.82万股，近20个交易日中有13个交易日出现融券净卖出。 小知识 融资融券 ...

格隆汇10月13日丨上海莱士(002252.SZ)在投资者互动平台表示，公司正在积极推进广西莱士的复工复 产工作，各项工作按照已披露的规划和安排正常推进。目前，广西莱士正处于试生产阶段。 ...

Group 1 - The company Shanghai Laishi Blood Products Co., Ltd. announced the progress of its share repurchase plan on October 10, 2025 [1] - The repurchase plan was approved on January 13, 2025, with a total fund of no less than 250 million yuan and no more than 500 million yuan, with a maximum repurchase price of 9.55 yuan per share [2] - As of the end of September 2025, the company had repurchased a total of 70,974,175 shares at a minimum price of 6.62 yuan per share, with a total transaction amount of approximately 469.85 million yuan [3] Group 2 - The company confirmed that the repurchase complies with the established plan and relevant legal regulations, ensuring that no major events affecting the stock price occurred during the repurchase period [4] - The company will continue to advance the repurchase plan based on market conditions and will fulfill information disclosure obligations as required [4]

Group 1 - The company Shanghai Laishi (SZ 002252) announced on October 9 that it has repurchased approximately 68.32 million shares, accounting for 1.03% of its total share capital, with a total transaction amount of about 470 million yuan [1][1][1] - The highest transaction price during the share buyback was 7.09 yuan per share, while the lowest was 6.62 yuan per share [1][1][1] - As of the report, Shanghai Laishi's market capitalization stands at 45 billion yuan [1][1][1] Group 2 - For the first half of 2025, the company's revenue composition shows that blood product production and sales accounted for 99.21%, while testing equipment and reagents made up 0.76%, and other businesses contributed 0.03% [1][1][1]

Core Viewpoint - Shanghai Laishi (002252.SZ) has announced a share buyback program, indicating a commitment to returning value to shareholders through the repurchase of its own shares [1] Summary by Categories Share Buyback Details - The company has repurchased a total of 68,321,952 shares, which represents 1.03% of its total share capital [1] - The highest transaction price during the buyback was 7.09 CNY per share, while the lowest was 6.62 CNY per share [1] - The total amount spent on the buyback reached 469,849,037.98 CNY, excluding transaction commissions and other fees [1]

证券代码：002252 证券简称：上海莱士 公告编号：2025-064 上述回购符合公司既定回购股份方案及相关法律法规的要求。 上海莱士血液制品股份有限公司（"公司"）于 2025 年 1 月 13 日召开了第六 届董事会第七次（临时）会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有或自筹资金以集中竞价交易方式从二级市场回购公司股份，用 于实施员工持股计划或股权激励，拟回购股份的资金总额为不低于人民币 2.5 亿 元（含）且不超过人民币 5 亿元（含），拟回购股份价格不超过人民币 9.55 元/ 股（含），具体回购股份数量以回购股份方案实施完毕或回购实施期限届满时实 际回购情况为准。回购期限自股东大会审议通过本次回购股份方案之日起 12 个 月内，如果触及回购股份方案提及的相关条件时，回购期限提前届满。公司于 2025 年 2 月 14 日召开 2025 年第一次临时股东大会审议通过了上述股份回购方 案。具体内容详见公司分别于 2025 年 1 月 14 日、2025 年 2 月 15 日在《证券时 报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网（www.cninfo.com ...